For the year ending 2025-12-31, APLS had $55,148K increase in cash & cash equivalents over the period. $45,014K in free cash flow.
| Cash Flow | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Net income/(loss) | 22,388 | -197,878 | -528,628 | -652,172 |
| Share-based compensation expense | 104,003 | 114,128 | 105,945 | 91,085 |
| Loss on conversion of debt | - | - | - | 32,890 |
| Forfeiture of accrued interest in exchange of convertible notes | - | - | - | 1,287 |
| Loss on disposal of fixed assets | - | - | -120 | - |
| Loss on extinguishment of development liability | - | 1,949 | - | - |
| Depreciation expense | 1,558 | 1,797 | 1,784 | 1,552 |
| Amortization of right of use assets | - | - | -80 | -65 |
| Amortization of discounts for credit facility | - | 1,250 | - | - |
| Amortization of discounts for convertible notes, net of financing costs | - | - | 297 | 459 |
| Amortization of discounts for convertible notes | - | 309 | - | - |
| Accretion of discount to development liability | - | 8,936 | 25,996 | 26,917 |
| Amortization of discounts for credit facility and convertible notes | 2,496 | - | - | - |
| Accounts receivable | 101,279 | 58,484 | 198,715 | -2,375 |
| Inventory | 15,267 | 10,755 | 60,647 | 69,397 |
| Prepaid assets | - | -20,420 | 1,870 | 11,479 |
| Other current assets | - | -10,793 | -14,243 | -32,936 |
| Prepaid and other current assets | 8,087 | - | - | - |
| Other assets | 4,061 | -705 | -11,700 | -17,490 |
| Right-of-use assets and lease liabilities | -34 | -277 | - | - |
| Accounts payable | 18,223 | 1,089 | 170 | 18,689 |
| Accrued expenses and other liabilities | 25,387 | 18,152 | 34,950 | -6,312 |
| Net cash provided by/(used in) operating activities | 45,327 | -87,866 | -594,735 | -513,745 |
| Purchase of property and equipment | 313 | 403 | 773 | 1,524 |
| Purchase of available-for-sale securities | - | - | - | 331,863 |
| Proceeds from maturity of available-for-sale securities | - | - | - | 393,280 |
| Proceeds from sale of fixed assets | - | - | 99 | - |
| Net cash used in investing activities | -313 | -403 | -674 | 59,893 |
| Proceeds from credit facility | - | 365,454 | - | - |
| Payment of issuance cost for credit facility | - | 7,214 | - | - |
| Proceeds from issuance of common stock, net of issuance costs | - | - | - | 380,120 |
| Proceeds from issuance of common stock, pre-funded warrant offering, net of issuance costs | - | - | 384,387 | - |
| Repayment of development liability | - | 326,533 | - | - |
| Payments for development liability | - | - | 55,500 | 34,500 |
| Proceeds from settlement of capped call | - | 98,763 | - | - |
| Proceeds from exercise of stock options and warrants | - | - | - | 21,483 |
| Proceeds from exercise of stock options | 5,545 | 14,316 | 71,274 | - |
| Proceeds from issuance of common stock under employee share purchase plan | 3,350 | 4,512 | 5,378 | 4,238 |
| Payments of employee tax withholding related to equity-based compensation | 11 | 57 | 11,040 | 5,682 |
| Net cash provided by financing activities | 8,884 | 149,241 | 394,499 | 365,659 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | 1,250 | -659 | 135 | -488 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 55,148 | 60,313 | -200,775 | -88,681 |
| Cash, cash equivalents and restricted cash at beginning of period | 412,612 | 352,299 | 553,074 | 641,755 |
| Cash, cash equivalents and restricted cash at end of period | 467,760 | 412,612 | 352,299 | 553,074 |
Apellis Pharmaceuticals, Inc. (APLS)
Apellis Pharmaceuticals, Inc. (APLS)